Coherus Oncology, Inc. in brief
Coherus Oncology, Inc. is a listed company in the Biotechnology industry, based in Redwood City, California, USA. In the year to December 2025 it had sales of $42 M and a net profit of $168 M. Its largest product and service lines by sales in 2025 were Toripalimab (97%). Its shares trade under the symbol CHRS (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Coherus Oncology, Inc.
We are a fully integrated commercial-stage innovative oncology company with an approved next-generation programmed death receptor-1 inhibitor, LOQTORZI® (toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting liver, head and neck, colorectal and other cancers. Our strategy is to grow sales of LOQTORZI in nasopharyngeal carcinoma and advance the development of new indications for LOQTORZI in combination with both our pipeline candidates as well as our partners, driving sales multiples and synergies from proprietary combinations. On May 29, 2025, we changed our corporate name from “Coherus BioSciences, Inc.” to “Coherus Oncology, Inc.” to better align with our exclusive focus on proprietary innovative immuno-oncology medicines following the completion of the recent divestitures of our biosimilar businesses.
From the company's annual report filed with the US SEC: read the report
Coherus Oncology, Inc. timeline
- 2011
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2012
- ✎Renamed Coherus BioSciences, Inc.Formerly BioGenerics, Inc..
- 2014
- 🔔Initial public offering as Coherus BioSciences, Inc.Final prospectus filed with the SEC on 6 November 2014; shares registered for exchange trading on 3 November 2014.
- 2020
- 💰Record revenue of $476 millionFY2020, the highest of the 7 years on record.
- 2025
- 💰Record net income of $168 millionFY2025, the highest profit of the 4 years on record.
- ✎Renamed Coherus Oncology, Inc.Formerly Coherus BioSciences, Inc..
Events of Coherus Oncology, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
Not enough history yet.
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin (TTM)
- -253.4%
- Operating margin
- -429.5%
- Return on equity
- -222.8%
- Liabilities / assets
- 76.4%
- Net debt
- $-104M
- Revenue growth
- +59.8%
- R&D / revenue
- 258.2%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $42M | +59.8% | $-181M | $168M | 398.4% |
| Dec 2024 | $26M | +2063.1% | $-200M | $29M | 108.0% |
| Dec 2023 | $1M | -99.4% | $-216M | $-238M | -19499.2% |
| Dec 2022 | $211M | -35.4% | $-257M | $-292M | -138.2% |
| Dec 2021 | $327M | -31.4% | $-264M | $-287M | -87.9% |
| Dec 2020 | $476M | +33.6% | $156M | $132M | 27.8% |
| Dec 2019 | $356M | — | $108M | $90M | 25.2% |
| Dec 2018 | — | — | $-204M | $-209M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-139M | — | — | $1.43 | — |
| Dec 2024 | $-20M | — | — | $0.25 | — |
| Dec 2023 | $-175M | $0M | $-175M | $-2.53 | — |
| Dec 2022 | $-241M | $2M | $-243M | $-3.76 | — |
| Dec 2021 | $-37M | $1M | $-39M | $-3.81 | — |
| Dec 2020 | $154M | $7M | $147M | $1.62 | — |
| Dec 2019 | $28M | $2M | $27M | $1.23 | — |
| Dec 2018 | $-159M | $1M | $-160M | $-3.22 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $14M (+23.3% on a year earlier), net income $-39M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 9, 202610-QQuarterly report · period to Sep 2026
- Nov 9, 20268-KCurrent reportResults of operations
- Oct 29, 20268-KCurrent reportRegulation FD disclosure · Other events
- Aug 28, 20268-KCurrent reportOther events
- Aug 17, 20268-KCurrent reportRegulation FD disclosure · Other events
- Aug 17, 20268-KCurrent reportMaterial agreement · Agreement ended · New financial obligation
- Aug 5, 202610-QQuarterly report · period to Jun 2026
- Aug 5, 20268-KCurrent reportResults of operations
- Jun 15, 20268-KCurrent reportAuditor change
- Jun 1, 20268-KCurrent reportShareholder vote
- May 11, 202610-QQuarterly report · period to Mar 2026
- May 11, 20268-KCurrent reportResults of operations
Official filings of Coherus Oncology, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $42 M
- Operating income
- $-181 M
- Net income
- $168 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $258 M
- Total liabilities
- $197 M
- Total equity
- $61 M
As of December-2025
Top 100 institutional investors in Coherus Oncology, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Timothy G. Youngquist 2020 Irrevocable Trust | 13,050,623 | 0 (0.00%) | 8.44% | $16 M | Oct 13, 2026 |
| 2 | BlackRock, Inc. | 11,742,006 | -261,310 (-2.18%) | 7.60% | $14 M | Nov 13, 2026 |
| 3 | Vanguard Capital Management LLC | 5,598,339 | -351,151 (-5.90%) | 3.62% | $7 M | Nov 13, 2026 |
| 4 | Samsara Biocapital, LLC | 3,383,565 | -45,006 (-1.31%) | 2.19% | $4 M | Nov 16, 2026 |
| 5 | Geode Capital Management, LLC | 3,098,735 | -586,832 (-15.92%) | 2.01% | $4 M | Nov 6, 2026 |
| 6 | Kohlberg Kravis Roberts & Co. L.P. | 3,036,076 | 0 (0.00%) | 1.96% | $4 M | Nov 13, 2026 |
| 7 | State Street Corp | 2,426,779 | +44,474 (+1.87%) | 1.57% | $3 M | Nov 12, 2026 |
| 8 | CM Management, LLC | 2,100,000 | 0 (0.00%) | 1.36% | $3 M | Nov 12, 2026 |
| 9 | Goldman Sachs Group Inc | 1,995,469 | +1,393,394 (+231.43%) | 1.29% | $2 M | Nov 16, 2026 |
| 10 | C WorldWide Group Holding A/S | 1,928,464 | 0 (0.00%) | 1.25% | $2 M | Nov 4, 2026 |
| 11 | ADAR1 Capital Management, LLC | 1,886,346 | +1,875,980 (+18097.43%) | 1.22% | $2 M | Nov 16, 2026 |
| 12 | Hudson Bay Capital Management LP | 1,733,000 | +40,000 (+2.36%) | 1.12% | $2 M | Nov 13, 2026 |
| 13 | Charles Schwab Investment Management Inc | 1,218,004 | -10,065 (-0.82%) | 0.79% | $1 M | Nov 16, 2026 |
| 14 | UBS Group AG | 1,028,832 | +268,474 (+35.31%) | 0.67% | $1 M | Nov 10, 2026 |
| 15 | Northern Trust Corp | 1,018,742 | -110,728 (-9.80%) | 0.66% | $1 M | Nov 16, 2026 |
| 16 | Renaissance Technologies LLC | 941,828 | +378,772 (+67.27%) | 0.61% | $1 M | Nov 12, 2026 |
| 17 | Panagora Asset Management Inc | 907,876 | -229,449 (-20.17%) | 0.59% | $1 M | Nov 12, 2026 |
| 18 | Nomura Asset Management International Inc. | 900,000 | +1 (0.00%) | 0.58% | $1 M | Nov 16, 2026 |
| 19 | Vanguard Fiduciary Trust Co | 886,320 | -129,671 (-12.76%) | 0.57% | $1 M | Nov 13, 2026 |
| 20 | Vanguard Portfolio Management LLC | 833,694 | -49,760 (-5.63%) | 0.54% | $1 M | Nov 13, 2026 |
| 21 | Bank Of America Corp /de/ | 424,202 | +121,674 (+40.22%) | 0.27% | $1 M | Nov 16, 2026 |
| 22 | Invesco Ltd. | 371,021 | +17,099 (+4.83%) | 0.24% | $0 M | Nov 12, 2026 |
| 23 | Bank of New York Mellon Corp | 331,077 | +11,390 (+3.56%) | 0.21% | $0 M | Nov 5, 2026 |
| 24 | Citadel Advisors LLC | 282,191 | +240,080 (+570.11%) | 0.18% | $0 M | Nov 16, 2026 |
| 25 | Nuveen, LLC | 279,842 | +29,093 (+11.60%) | 0.18% | $0 M | Nov 10, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Morgan Stanley | 277,922 | +47,174 (+20.44%) | 0.18% | $0 M | Nov 13, 2026 |
| 27 | Barclays PLC | 230,929 | +29,786 (+14.81%) | 0.15% | $0 M | Nov 6, 2026 |
| 28 | Alliancebernstein L.P. | 221,900 | 0 (0.00%) | 0.14% | $0 M | Nov 16, 2026 |
| 29 | AQR Capital Management LLC | 218,597 | -1,111,604 (-83.57%) | 0.14% | $0 M | Nov 16, 2026 |
| 30 | Millennium Management LLC | 196,342 | +175,593 (+846.27%) | 0.13% | $0 M | Nov 16, 2026 |
| 31 | Bridgeway Capital Management, LLC | 175,000 | -216,000 (-55.24%) | 0.11% | $0 M | Nov 16, 2026 |
| 32 | Empowered Funds, LLC | 175,000 | New | 0.11% | $0 M | Nov 13, 2026 |
| 33 | DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | 159,990 | 0 (0.00%) | 0.10% | $0 M | Nov 16, 2026 |
| 34 | Acadian Asset Management LLC | 156,198 | +6,971 (+4.67%) | 0.10% | $0 M | Nov 9, 2026 |
| 35 | Citigroup Inc | 154,112 | +89,770 (+139.52%) | 0.10% | $0 M | Nov 4, 2026 |
| 36 | Rhumbline Advisers | 146,206 | +3,845 (+2.70%) | 0.09% | $0 M | Nov 10, 2026 |
| 37 | Tyche Wealth Partners LLC | 144,202 | -57,000 (-28.33%) | 0.09% | $0 M | Nov 10, 2026 |
| 38 | Summit Financial, LLC | 114,834 | -27 (-0.02%) | 0.07% | $0 M | Nov 12, 2026 |
| 39 | Deutsche Bank AG\ | 111,614 | -16,007 (-12.54%) | 0.07% | $0 M | Nov 6, 2026 |
| 40 | Price T Rowe Associates Inc /MD/ | 108,750 | 0 (0.00%) | 0.07% | $0 M | Nov 16, 2026 |
| 41 | Shay Capital LLC | 105,326 | 0 (0.00%) | 0.07% | $0 M | Nov 16, 2026 |
| 42 | Corient Private Wealth LP | 100,005 | +5 (+0.01%) | 0.06% | $0 M | Nov 16, 2026 |
| 43 | HSBC Holdings PLC | 91,895 | 0 (0.00%) | 0.06% | $0 M | Nov 16, 2026 |
| 44 | XTX Topco Ltd | 85,247 | -38,250 (-30.97%) | 0.06% | $0 M | Nov 16, 2026 |
| 45 | SEI Investments Co | 76,629 | 0 (0.00%) | 0.05% | $0 M | Nov 10, 2026 |
| 46 | PVG Asset Management Corp | 74,160 | -59,075 (-44.34%) | 0.05% | $0 M | Oct 19, 2026 |
| 47 | SteelPeak Wealth, LLC | 71,408 | +2,408 (+3.49%) | 0.05% | $0 M | Oct 16, 2026 |
| 48 | Jpmorgan Chase & Co | 69,361 | +3,295 (+4.99%) | 0.04% | $0 M | Nov 12, 2026 |
| 49 | Strs Ohio | 68,200 | -327,400 (-82.76%) | 0.04% | $0 M | Oct 30, 2026 |
| 50 | Envestnet Asset Management Inc | 63,823 | -77,047 (-54.69%) | 0.04% | $0 M | Nov 16, 2026 |
| 51 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 63,369 | +3,183 (+5.29%) | 0.04% | $0 M | Nov 16, 2026 |
| 52 | HRT Financial LP | 61,058 | New | 0.04% | $0 M | Nov 13, 2026 |
| 53 | Susquehanna International Group, LLP | 58,924 | -50,703 (-46.25%) | 0.04% | $0 M | Nov 16, 2026 |
| 54 | Vanguard Global Advisers, LLC | 58,421 | +612 (+1.06%) | 0.04% | $0 M | Nov 13, 2026 |
| 55 | Canton Hathaway, LLC | 58,230 | 0 (0.00%) | 0.04% | $0 M | Oct 23, 2026 |
| 56 | Russell Investments Group, Ltd. | 50,613 | 0 (0.00%) | 0.03% | $0 M | Nov 6, 2026 |
| 57 | LPL Financial LLC | 45,967 | -2,200 (-4.57%) | 0.03% | $0 M | Nov 6, 2026 |
| 58 | International Assets Investment Management, LLC | 45,501 | +2,543 (+5.92%) | 0.03% | $0 M | Nov 2, 2026 |
| 59 | Quadrature Capital Ltd | 43,371 | New | 0.03% | $0 M | Nov 13, 2026 |
| 60 | Cambridge Investment Research Advisors, Inc. | 42,186 | -62,566 (-59.73%) | 0.03% | $0 M | Nov 2, 2026 |
| 61 | BNP Paribas Financial Markets | 37,754 | +11,321 (+42.83%) | 0.02% | $0 M | Nov 12, 2026 |
| 62 | Manufacturers Life Insurance Company, The | 37,474 | -1,146 (-2.97%) | 0.02% | $0 M | Nov 13, 2026 |
| 63 | Vanguard Personalized Indexing Management, LLC | 34,228 | +1,078 (+3.25%) | 0.02% | $0 M | Nov 16, 2026 |
| 64 | Cetera Investment Advisers | 33,363 | +1,436 (+4.50%) | 0.02% | $0 M | Nov 13, 2026 |
| 65 | Boothbay Fund Management, LLC | 32,292 | +17,005 (+111.24%) | 0.02% | $0 M | Nov 16, 2026 |
| 66 | Leonteq Securities AG | 30,746 | New | 0.02% | $0 M | Oct 29, 2026 |
| 67 | Wells Fargo & Company/mn | 29,488 | -83,415 (-73.88%) | 0.02% | $0 M | Nov 16, 2026 |
| 68 | Police & Firemen's Retirement System of New Jersey | 28,230 | 0 (0.00%) | 0.02% | $0 M | Nov 9, 2026 |
| 69 | China Universal Asset Management Co., Ltd. | 28,190 | +3,641 (+14.83%) | 0.02% | $0 M | Oct 28, 2026 |
| 70 | Voya Investment Management LLC | 27,652 | 0 (0.00%) | 0.02% | $0 M | Nov 10, 2026 |
| 71 | Raymond James Financial Inc | 27,102 | New | 0.02% | $0 M | Nov 12, 2026 |
| 72 | Two Sigma Securities, LLC | 26,613 | +16,570 (+164.99%) | 0.02% | $0 M | Nov 16, 2026 |
| 73 | Ieq Capital, LLC | 25,541 | -136,812 (-84.27%) | 0.02% | $0 M | Nov 10, 2026 |
| 74 | Brevan Howard Capital Management LP | 25,371 | New | 0.02% | $0 M | Nov 16, 2026 |
| 75 | Centiva Capital, LP | 22,141 | New | 0.01% | $0 M | Nov 13, 2026 |
| 76 | Atria Investments, Inc | 21,827 | -4,599 (-17.40%) | 0.01% | $0 M | Oct 15, 2026 |
| 77 | Prudential Financial Inc | 20,835 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 78 | ProShare Advisors LLC | 20,700 | -1,472 (-6.64%) | 0.01% | $0 M | Oct 29, 2026 |
| 79 | New York State Common Retirement Fund | 20,593 | 0 (0.00%) | 0.01% | $0 M | Nov 17, 2026 |
| 80 | Medallion Wealth Advisors, LLC | 20,000 | +5,000 (+33.33%) | 0.01% | $0 M | Nov 13, 2026 |
| 81 | Wealth Enhancement Advisory Services, LLC | 19,322 | -42,933 (-68.96%) | 0.01% | $0 M | Oct 13, 2026 |
| 82 | Cerity Partners LLC | 19,262 | -55,345 (-74.18%) | 0.01% | $0 M | Nov 13, 2026 |
| 83 | Stratos Wealth Partners, LTD. | 16,131 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 84 | Bronte Capital Management Pty Ltd. | 15,262 | 0 (0.00%) | 0.01% | $0 M | Nov 12, 2026 |
| 85 | Dimensional Fund Advisors LP | 15,055 | -20,342 (-57.47%) | 0.01% | $0 M | Nov 4, 2026 |
| 86 | Providence Wealth Advisors, LLC | 15,000 | 0 (0.00%) | 0.01% | $0 M | Oct 29, 2026 |
| 87 | Kingsbury Capital Investment Advisors LLC | 14,545 | +2,149 (+17.34%) | 0.01% | $0 M | Oct 20, 2026 |
| 88 | Wealth Group, Ltd. | 14,195 | New | 0.01% | $0 M | Oct 30, 2026 |
| 89 | Jane Street Group, LLC | 13,528 | -25,135 (-65.01%) | 0.01% | $0 M | Nov 12, 2026 |
| 90 | StoneX Group Inc. | 13,454 | New | 0.01% | $0 M | Nov 3, 2026 |
| 91 | Victory Capital Management Inc | 13,184 | -242 (-1.80%) | 0.01% | $0 M | Nov 10, 2026 |
| 92 | Vontobel Holding Ltd. | 13,066 | New | 0.01% | $0 M | Oct 16, 2026 |
| 93 | Legal & General Group Plc | 12,714 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 94 | CIBC Bancorp USA Inc. | 12,603 | New | 0.01% | $0 M | Nov 13, 2026 |
| 95 | Xponance LLC | 12,218 | -216 (-1.74%) | 0.01% | $0 M | Nov 3, 2026 |
| 96 | Endowment Wealth Management, Inc. | 11,521 | 0 (0.00%) | 0.01% | $0 M | Nov 3, 2026 |
| 97 | EFG International AG | 11,500 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 98 | TRB Wealth Management, LLC | 11,326 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 99 | Group One Trading LLC | 11,323 | -9,523 (-45.68%) | 0.01% | $0 M | Nov 10, 2026 |
| 100 | Neuberger Berman Group LLC | 10,605 | -3,783 (-26.29%) | 0.01% | $0 M | Nov 13, 2026 |
Mutual funds holding Coherus Oncology, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 3.95 M | $6 M | 2.6% | <0.01% | +8.9% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 3.22 M | $5 M | 2.1% | <0.01% | +29% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 1.86 M | $3 M | 1.2% | <0.01% | +10% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 1.42 M | $2 M | 0.92% | <0.01% | +40% | Jul 31, 2026 |
| 🇺🇸 BlackRock Advantage Small Cap Core FundBlackRock Advisors, LLC | 927,830 | $1 M | 0.60% | 0.03% | −1.2% | May 29, 2026 |
| 🇺🇸 Nomura Healthcare FundDelaware Management Company | 900,000 | $1 M | 0.58% | 0.17% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 783,155 | $1 M | 0.51% | <0.01% | +22% | May 31, 2026 |
| 🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc. | 709,098 | $1 M | 0.46% | <0.01% | +20% | May 31, 2026 |
| 🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors | 741,539 | $1 M | 0.48% | <0.01% | +17% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 535,033 | $1 M | 0.35% | <0.01% | +2.1% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 438,059 | $1 M | 0.28% | 0.04% | +68% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 436,778 | $1 M | 0.28% | <0.01% | +71% | Jun 30, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 318,186 | $0 M | 0.21% | <0.01% | +36% | Jul 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 267,846 | $0 M | 0.17% | <0.01% | +12% | May 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 274,247 | $0 M | 0.18% | <0.01% | +39% | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 227,152 | $0 M | 0.15% | <0.01% | +31% | May 31, 2026 |
| 🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC | 210,439 | $0 M | 0.14% | 0.01% | −9.6% | Jul 31, 2026 |
| 🇺🇸 BlackRock Advantage Small Cap Growth FundBlackRock Funds | 203,071 | $0 M | 0.13% | 0.03% | +30% | Jun 30, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 200,000 | $0 M | 0.13% | 0.19% | +33% | Jun 30, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 174,120 | $0 M | 0.11% | <0.01% | +30% | Jul 31, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 142,268 | $0 M | 0.09% | <0.01% | +48% | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 127,980 | $0 M | 0.08% | <0.01% | +6.9% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 117,771 | $0 M | 0.08% | <0.01% | +34% | Jun 30, 2026 |
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 1.71 M | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 109,420 | $0 M | 0.07% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 91,739 | $0 M | 0.06% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Schwab U.S. Broad Market ETFCharles Schwab Investment Management, Inc. | 91,696 | $0 M | 0.06% | <0.01% | +1.6% | May 31, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 83,840 | $0 M | 0.05% | <0.01% | −6.5% | Jul 31, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 79,950 | $0 M | 0.05% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 AQR Small Cap Multi-Style FundAQR CAPITAL MANAGEMENT, LLC | 78,726 | $0 M | 0.05% | 0.03% | −18% | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 76,969 | $0 M | 0.05% | <0.01% | +31% | Jun 30, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 76,805 | $0 M | 0.05% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 68,166 | $0 M | 0.04% | <0.01% | +26% | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 67,253 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 65,031 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 62,442 | $0 M | 0.04% | <0.01% | +39% | Jul 31, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 61,963 | $0 M | 0.04% | <0.01% | +19% | Jul 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc. | 54,650 | $0 M | 0.04% | <0.01% | +4.6% | May 31, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 42,500 | $0 M | 0.03% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 46,222 | $0 M | 0.03% | <0.01% | +26% | Jun 30, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 45,358 | $0 M | 0.03% | <0.01% | +68% | Jun 30, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 44,576 | $0 M | 0.03% | <0.01% | +30% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 43,837 | $0 M | 0.03% | <0.01% | +73% | Jun 30, 2026 |
| 🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors | 43,427 | $0 M | 0.03% | <0.01% | −24% | Jun 30, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 42,517 | $0 M | 0.03% | <0.01% | +12% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 579,706 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P. | 37,384 | $0 M | 0.02% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 AQR Small Cap Momentum Style FundAQR CAPITAL MANAGEMENT, LLC | 30,915 | $0 M | 0.02% | 0.03% | — | Mar 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc. | 32,543 | $0 M | 0.02% | <0.01% | +3.0% | May 31, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC | 36,015 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Clearwater Select Equity FundClearwater Management Co Inc. | 32,477 | $0 M | 0.02% | <0.01% | −32% | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 29,359 | $0 M | 0.02% | 0.02% | +62% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 29,001 | $0 M | 0.02% | <0.01% | +51% | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 28,077 | $0 M | 0.02% | <0.01% | +51% | Jun 30, 2026 |
| 🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC | 23,497 | $0 M | 0.02% | <0.01% | +4.6% | Jul 31, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 22,239 | $0 M | 0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Goldman Sachs Variable Insurance Trust Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P. | 21,782 | $0 M | 0.01% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 21,016 | $0 M | 0.01% | <0.01% | +70% | Jun 30, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 20,484 | $0 M | 0.01% | <0.01% | +34% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 19,935 | $0 M | 0.01% | <0.01% | +93% | Jun 30, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 17,535 | $0 M | 0.01% | <0.01% | +67% | Jun 30, 2026 |
| 🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION | 14,800 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors | 16,634 | $0 M | 0.01% | <0.01% | −0.8% | Jun 30, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 14,072 | $0 M | <0.01% | <0.01% | −47% | May 31, 2026 |
| 🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP | 15,055 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 13,426 | $0 M | <0.01% | <0.01% | −4.9% | Jul 31, 2026 |
| 🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC | 12,362 | $0 M | <0.01% | <0.01% | +3.4% | Jun 30, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 11,838 | $0 M | <0.01% | <0.01% | −0.3% | Jul 31, 2026 |
| 🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP | 11,365 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC | 10,821 | $0 M | <0.01% | <0.01% | +45% | Jun 30, 2026 |
| 🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC | 10,117 | $0 M | <0.01% | <0.01% | +57% | Jun 30, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 9,819 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc. | 9,355 | $0 M | <0.01% | <0.01% | −8.5% | Jun 30, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 9,257 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP | 8,977 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 8,784 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc. | 7,172 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC | 8,100 | $0 M | <0.01% | <0.01% | +2.5% | Jun 30, 2026 |
| 🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC | 6,777 | $0 M | <0.01% | <0.01% | +180% | Jul 31, 2026 |
| 🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC | 6,711 | $0 M | <0.01% | <0.01% | +5.7% | Jun 30, 2026 |
| 🇺🇸 iShares Total U.S. Stock Market Index FundBlackRock Advisors, LLC | 6,286 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC | 5,814 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC | 5,804 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC | 4,874 | $0 M | <0.01% | <0.01% | +6.1% | May 31, 2026 |
| 🇺🇸 Morgan Stanley Pathway Small-Mid Cap Equity ETFCONSULTING GROUP ADVISORY SERVICES LLC | 4,536 | $0 M | <0.01% | <0.01% | −5.3% | May 31, 2026 |
| 🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 4,547 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC | 3,812 | $0 M | <0.01% | <0.01% | −42% | May 31, 2026 |
| 🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC | 3,853 | $0 M | <0.01% | <0.01% | −41% | May 31, 2026 |
| 🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC | 3,989 | $0 M | <0.01% | <0.01% | +13% | Jul 31, 2026 |
| 🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS | 3,744 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC | 3,673 | $0 M | <0.01% | <0.01% | +32% | Jun 30, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 3,363 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC | 3,095 | $0 M | <0.01% | <0.01% | −28% | Jun 30, 2026 |
| 🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC | 2,921 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 2,752 | $0 M | <0.01% | <0.01% | +17% | Jun 30, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 2,726 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC | 1,851 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 24,474 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 15,512 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC | 732 | $0 M | <0.01% | <0.01% | +32% | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Coherus Oncology, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Charles W. NewtonDirector | Grant or award | +30,000 | — | — | 30,000 | Form 4 |
| filed | Rita A. KarachunDirector | Grant or award | +30,000 | — | — | 30,000 | Form 4 |
| filed | Lee Nisley NewcomerDirector | Grant or award | +30,000 | — | — | 30,000 | Form 4 |
| filed | Jill O'Donnell-TormeyDirector | Grant or award | +30,000 | — | — | 30,000 | Form 4 |
| filed | Ali J. SatvatDirector | Grant or award | +30,000 | — | — | 30,000 | Form 4 |
| filed | Mats WahlstromDirector | Grant or award | +30,000 | — | — | 30,000 | Form 4 |
| filed | Michael Lee RyanDirector | Grant or award | +30,000 | — | — | 30,000 | Form 4 |
| filed | Dennis M. LanfearPresident & CEO, Director | Grant or award | +375,000 | — | — | 1.05 M | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Coherus Oncology, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-1 split
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q4 2014 | Q4 2014 | $0M |
| Q3 2014 | Q3 2014 | $0M |
| Q2 2014 | Q2 2015 | $0M |
| Q1 2014 | Q1 2015 | $0M |
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Coherus Oncology, Inc. scorecard#
Passes 5 of the 12 checks that could be worked out: strongest in growth (3 of 4), weakest in profitability (1 of 4). Fiscal year 2025.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth3 of 4
- ✓Revenue grew in the newest year59.8%Revenue up 59.8% in fiscal 2025.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✓Earnings per share grew in the newest year1.43 vs 0.25Diluted EPS 1.43 in fiscal 2025 against 0.25 the year before (report's currency).
- ✓Net income higher than five years earlier$168 M$168 M in fiscal 2025 against $132 M in 2020.
- ✗Revenue rose in at least four of the last five years2 of 5Revenue rose in 2 of the five years to fiscal 2025.
Profitability1 of 4
- ✓Profitable in the newest year$168 MNet income $168 M in fiscal 2025.
- ✗Profitable in each of the last five years2 of 5Profitable in 2 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-429.5%-429.5% against Biotechnology's median of -60.5% (243 companies).
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- ✗Operating margin wider than three years earlier-429.5%-429.5% in fiscal 2025 against -121.7% in 2022.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities1.5×Current ratio 1.47 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- ✗Operating income covers interest five times-20.1×Operating income -20.1 times interest in fiscal 2025.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year2.3%Diluted shares up 2.3% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Coherus Oncology, Inc.'s statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -429.5% | -60.5% | |
| Net margin | 398.4% | -68.9% | |
| Revenue growth | 59.8% | 15.8% |
5of 8on the Piotroski tests of financial strength
- Only -82% of net income arrived as cash from operations.
- Operating income covers the interest bill only -20.1 times.
Coherus Oncology, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 42+59.8%100% | 26r267−89.7%100% | 257+21.9%100% | 211−35.4%100% | 327−31.4%100% | 476+33.6%100% | 356—100% | 0−100%— | 1.6−99.2%100% | 190—100% | |
| Cost of revenue | 14+58.3%32.8% | 8.7r118−94.5%33.1% | 159+127%61.8% | 70+21.7%33.2% | 58+52.9%17.6% | 38+121%7.9% | 17—4.8% | — | — | — | |
| Research and development | 109+18.6%258% | 92r93−16.1%348% | 109−45.1%42.5% | 199−45.1%94.5% | 363+154%111% | 143+51.6%30.0% | 94−14.6%26.5% | 110−32.1%— | 162−36.2%10436% | 254—134% | |
| Selling, general and administrative | 101−19.8%239% | 125r168−34.6%476% | 192−3.3%74.6% | 198+17.0%94.0% | 170+22.0%52.0% | 139+1.5%29.2% | 137+45.5%38.5% | 94+32.1%— | 71+38.2%4582% | 52—27.1% | |
| General and administrative | — | — | — | — | — | — | — | — | 71+38.2%4582% | 52—27.1% | |
| Operating expenses | — | — | — | — | — | — | 248+21.5%69.7% | 204−12.5%— | 234−23.6%15019% | 306—161% | |
| Total costs and expenses | 223−1.2%530% | 226r379−50.9%857% | 460−1.6%179% | 468−20.7%222% | 590+84.8%181% | 320+28.7%67.1% | 248+21.5%69.7% | 204—— | — | — | |
| Operating income | −181—−430% | −200r−112—−757% | −203—−79.0% | −257—−122% | −264−269%−80.8% | 156+45.1%32.9% | 108—30.3% | −204—— | −232—−14919% | −116—−61.0% | |
| Interest and finance income | 7.0+55.6%16.6% | 4.5+60.7%17.1% | 2.8+47.4%1.1% | 1.9+35.7%0.9% | 1.4+133%0.4% | 0.6−62.5%0.1% | 1.6+14.3%0.4% | 1.4—— | — | — | |
| Interest expense and finance costs | 9.0−16.1%21.3% | 11r27−73.5%40.7% | 41+24.8%15.8% | 32+41.4%15.4% | 23+8.5%7.0% | 21+20.3%4.4% | 18+81.8%4.9% | 9.7+1.4%— | 9.6+19.7%614% | 8.0—4.2% | |
| Other non-operating income (expense) | 7.0−8.0%16.6% | 7.6r3.4+39.4%28.9% | 5.5+43.1%2.1% | 3.8—1.8% | −0.3−151%−0.1% | 0.6−78.8%0.1% | 2.6−44.4%0.7% | 4.7+37.9%— | 3.4—219% | −3.9—−2.0% | |
| Income before tax | −183—−434% | −215r29—−816% | −238—−92.6% | −292—−138% | −287−312%−87.9% | 136+46.3%28.5% | 93—26.1% | −209—— | −238—−15314% | — | |
| Income tax | 0—0.0% | 0—0.0% | −0.4—−0.1% | 0—0.0% | 0−100%0.0% | 3.5+17.7%0.7% | 2.9—0.8% | 0—— | 0—0.0% | 0—0.0% | |
| Income from discontinued operations | 351+44.0%833% | 244—924% | — | — | — | — | — | — | — | — | |
| Net income including minority interests | 168+489%398% | 29—108% | −238—−92.5% | −292—−138% | −287−317%−87.9% | 132+47.2%27.8% | 90—25.2% | −209—— | −238—−15314% | −128—−67.2% | |
| Minority interests' share of net income | — | — | — | — | — | — | 0—0.0% | −0.1—— | −0.1—−7.5% | −0.5—−0.2% | |
| Net income attributable to shareholders | 168+489%398% | 29—108% | −238—−92.5% | −292—−138% | −287−317%−87.9% | 132+47.2%27.8% | 90—25.2% | −209—— | −238—−15307% | −127—−67.0% | |
| Earnings per share, basic | 1.43+472%— | 0.25—— | -2.53—— | -3.76—— | -3.81−306%— | 1.85+43.4%— | 1.29—— | -3.22—— | -4.48—— | -3.04—— | |
| Earnings per share, diluted | 1.43+472%— | 0.25—— | -2.53—— | -3.76—— | -3.81−335%— | 1.62+31.7%— | 1.23—— | -3.22—— | -4.48—— | -3.04—— | |
| Shares, weighted average (basic) | 117+2.3%— | 115+21.7%— | 94+21.3%— | 78+2.9%— | 75+5.7%— | 71+2.5%— | 70+7.1%— | 65+22.4%— | 53—— | — | |
| Shares, weighted average (diluted) | 117+2.3%— | 115r115+21.7%— | 94+21.3%— | 78+2.9%— | 75−9.6%— | 83+14.1%— | 73+12.5%— | 65+22.4%— | 53+26.8%— | 42—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 89−29.5%34.4% | 126+22.4%28.1% | 103+61.9%16.3% | 64−84.8%13.2% | 417−22.9%61.4% | 541+205%64.3% | 178+146%43.4% | 72r72−43.0%72.7% | 127+1.6%78.0% | 125—70.0% | |
| Short-term investments | 83—32.2% | — | 15−88.4%2.4% | 128—26.6% | — | — | 0—0.0% | 0—0.0% | — | — | |
| Receivables | 18−84.0%6.9% | 111−57.3%24.8% | 261+137%41.4% | 110−10.6%22.9% | 123−21.7%18.1% | 157+10.6%18.7% | 142—34.7% | 0—0.0% | — | 1.9—1.0% | |
| Inventory | 3.2−24.6%1.2% | 4.2r70−93.3%0.9% | 63+61.4%9.9% | 39+3.1%8.1% | 38−14.9%5.5% | 44+351%5.3% | 9.8+491%2.4% | 1.7—1.7% | — | — | |
| Other current assets | 6.2−39.0%2.4% | 10r12−7.9%2.3% | 11−51.6%1.8% | 23+112%4.8% | 11+92.4%1.6% | 5.6+13.1%0.7% | 5.0+5881%1.2% | 0.1−41.5%0.1% | 0.1−95.2%0.1% | 3.0—1.7% | |
| Current assets | 207−39.5%80.0% | 342−28.2%76.2% | 476+24.8%75.5% | 381−36.7%79.3% | 602−21.5%88.7% | 767+124%91.2% | 343+306%83.9% | 84−42.0%84.9% | 145−9.9%89.5% | 161—90.5% | |
| Property, plant and equipment | 1.3−47.8%0.5% | 2.6r2.8−49.7%0.6% | 5.1−41.5%0.8% | 8.8+12.0%1.8% | 7.8−22.7%1.2% | 10+73.1%1.2% | 5.8−12.3%1.4% | 6.7−47.9%6.7% | 13+18.6%7.9% | 11—6.0% | |
| Right-of-use (leased) assets | 3.0−34.6%1.1% | 4.5−23.6%1.0% | 5.9+3.9%0.9% | 5.7−30.6%1.2% | 8.2−17.7%1.2% | 10.0r10.0−6.5%1.2% | 11—2.6% | 0—0.0% | — | — | |
| Goodwill | — | — | 0.90.0%0.1% | 0.9r0.9+4.8%0.2% | 0.9r0.9−4.6%0.1% | 0.90.0%0.1% | 0.90.0%0.2% | 0.90.0%0.9% | 0.90.0%0.6% | 0.9—0.5% | |
| Other intangible assets | 20−19.3%7.7% | 25−65.4%5.5% | 72+1108%11.4% | 5.9r5.9+66.5%1.2% | 3.6r2.6+36.0%0.5% | 2.60.0%0.3% | 2.60.0%0.6% | 2.60.0%2.6% | 2.60.0%1.6% | 2.6—1.5% | |
| Total assets | 258−42.4%100% | 449−28.8%100% | 630+30.9%100% | 481−29.2%100% | 679−19.3%100% | 842+106%100% | 409+311%100% | 99−38.8%100% | 163−8.9%100% | 178—100% | |
| Accounts payable | 9.9−65.2%3.8% | 28−19.2%6.3% | 35+206%5.6% | 12−28.7%2.4% | 16+6.3%2.4% | 15−41.5%1.8% | 26+69.9%6.4% | 15−1.2%15.4% | 15−21.4%9.5% | 20—11.0% | |
| Current liabilities | 140−50.4%54.3% | 283−14.7%63.1% | 332+139%52.7% | 139−16.1%28.8% | 165+13.5%24.3% | 146+26.7%17.3% | 115+246%28.1% | 33+17.1%33.4% | 28−49.6%17.5% | 56—31.6% | |
| Lease liabilities (non-current) | 1.5−55.7%0.6% | 3.3−34.0%0.7% | 5.0+37.2%0.8% | 3.6−46.3%0.8% | 6.8−25.6%1.0% | 9.1−11.5%1.1% | 10—2.5% | 0—0.0% | — | — | |
| Total liabilities | 197−66.0%76.4% | 581−29.5%129% | 823+33.1%131% | 618+6.3%129% | 582+3.7%85.6% | 561+84.6%66.6% | 304+120%74.3% | 138+4.5%139% | 132−17.0%81.2% | 159—89.2% | |
| Retained earnings | −1,383—−535% | −1,551—−346% | −1,580—−251% | −1,342—−279% | −1,050—−155% | −763—−90.6% | −895—−219% | −985—−990% | −775—−477% | −537—−301% | |
| Shareholders' equity | 61—23.6% | −132—−29.4% | −193—−30.7% | −137−241%−28.6% | 98−65.2%14.4% | 281+167%33.4% | 105—25.7% | −39−226%−38.8% | 31r32+48.8%18.8% | 21—11.5% | |
| Minority interests | — | — | — | — | — | — | — | — | −1.3—−0.8% | −1.2—−0.7% | |
| Total equity | — | — | — | — | — | — | 105—25.7% | −39−226%−38.8% | 31+57.8%18.8% | 19—10.8% | |
| Total liabilities and equity | 258−42.4%100% | 449−28.8%100% | 630+30.9%100% | 481−29.2%100% | 679−19.3%100% | 842+106%100% | 409+311%100% | 99−38.8%100% | 163−8.9%100% | 178—100% | |
| Shares outstanding | 121+4.8%— | 116+3.0%— | 112+42.3%— | 79+2.5%— | 77+6.1%— | 73+3.1%— | 70+3.0%— | 68+14.1%— | 60+30.6%— | 46r39—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 1.3−18.8%3.1% | 1.6r1.8−50.0%6.1% | 3.2−11.1%1.2% | 3.6r3.7+2.9%1.7% | 3.5r3.5+21.2%1.1% | 2.9−11.4%0.6% | 3.3+0.7%0.9% | 3.2−4.8%— | 3.4+13.4%218% | 3.0—1.6% | |
| Share-based compensation | 17−39.0%40.2% | 28−35.5%105% | 43−15.0%16.8% | 51−1.2%24.0% | 51+34.6%15.7% | 38+13.6%8.0% | 34−3.5%9.4% | 35+4.2%— | 33+21.8%2146% | 27—14.4% | |
| Cash from operating activities | −139—−328% | −20—−77.5% | −175—−68.0% | −241—−114% | −37−124%−11.5% | 154+444%32.4% | 28—8.0% | −159—— | −200—−12872% | −253—−133% | |
| Capital expenditure | — | — | −0.3—−0.1% | −2.0—−1.0% | −1.3—−0.4% | −7.2—−1.5% | −1.8—−0.5% | −0.8—— | −4.6—−294% | −6.5—−3.4% | |
| Cash from investing activities | 375+62.9%889% | 230+59.2%873% | 145—56.2% | −167—−79.1% | −138—−42.4% | −14—−3.0% | −13—−3.6% | −1.2—— | −4.4—−284% | −6.5—−3.4% | |
| Debt issued | — | — | — | 241—114% | — | — | — | — | — | — | |
| Debt repaid | — | −260—−987% | — | −82—−38.7% | — | — | — | — | — | — | |
| Shares issued | — | 1.5—5.5% | — | — | 41—12.5% | — | — | — | — | — | |
| Cash from financing activities | −274—−649% | −187−369%−709% | 70+28.1%27.1% | 54+4.7%25.7% | 52−76.8%15.9% | 224+151%47.1% | 89−15.2%25.1% | 105−49.0%— | 207−8.6%13290% | 226—119% | |
| Exchange-rate effect on cash | — | — | — | — | — | — | −0.3−159%−0.1% | 0.5—— | −0.1—−7.7% | −0.4—−0.2% | |
| Change in cash | −37−262%−88.0% | 23−41.8%86.8% | 39—15.3% | −354—−168% | −124−134%−38.0% | 364+247%76.4% | 105—29.4% | −55−2878%— | 2.0—126% | −33—−17.5% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 54+44.4%100% | 14+23.4%100% | 14+39.5%100% | 12+62.0%100% | 13*+64.9%100% | 12+91.2%100% | 10−0.4%100% | 7.6+229%100% | 7.7r54*−91.6%100% | 6.1r71—100% | 10r65—100% | 2.3r77—100% | 92*—100% | |
| Cost of revenue | 16+29.3%30.2% | 4.1+10.0%28.7% | 4.2+24.9%29.6% | 3.8+43.8%31.0% | 4.0*+47.1%31.7% | 3.7+36.4%32.2% | 3.4+87.7%33.1% | 2.7+84.4%34.9% | 2.8r34*−96.7%35.6% | 2.7r21—45.1% | 1.8r28—17.6% | 1.4r35—62.3% | 85*—92.4% | |
| Research and development | 97−2.1%180% | 23−17.0%158% | 21−18.5%150% | 22−11.5%175% | 31*+49.2%243% | 27+23.6%236% | 26+27.7%257% | 24−14.3%321% | 21r21*−21.3%268% | 22r22—364% | 21r22—200% | 28r28—1232% | 26*—28.8% | |
| Selling, general and administrative | 89−16.6%166% | 21−14.9%149% | 21−19.5%146% | 23−11.2%188% | 24*−20.3%185% | 25−11.4%215% | 26−5.4%254% | 26−35.3%342% | 30r41*−40.2%383% | 28r35—465% | 28r35—267% | 40r57—1743% | 49*—54.1% | |
| Total costs and expenses | 202−7.4%376% | 48−14.3%336% | 47−16.3%326% | 48−8.6%394% | 59*+10.4%460% | 56+5.7%483% | 56+11.7%544% | 53−24.3%698% | 53r96*−66.9%687% | 53r77—874% | 50r85—485% | 70r120—3037% | 160*—175% | |
| Operating income | −148—−276% | −34—−236% | −32—−226% | −36—−294% | −46*—−360% | −44—−383% | −45—−444% | −45—−598% | −45r−42*—−587% | −47r−6.4—−774% | −40r−21—−385% | −68r−43—−2937% | −69*—−75.3% | |
| Interest expense and finance costs | 9.5+10.1%17.8% | 2.8+19.6%19.5% | 2.3+2.0%16.2% | 2.2+1.7%17.8% | 2.2*+17.6%17.6% | 2.3−17.8%20.1% | 2.3−43.9%22.2% | 2.2−31.0%28.3% | 1.9r5.3*−82.0%24.7% | 2.8r5.4—46.7% | 4.1r5.3—39.5% | 3.1r11—135% | 11*—11.6% | |
| Other non-operating income (expense) | 5.4−15.9%10.1% | 0.9−57.1%6.4% | 1.3−54.9%9.1% | 1.4+650%11.4% | 1.8*+48.1%14.0% | 2.1+2.7%18.5% | 2.9+97.8%28.3% | 0.2−93.5%2.5% | 1.2r−3.0*—15.6% | 2.1—34.4% | 1.5—14.2% | 2.9—124% | −0.1*—−0.1% | |
| Income before tax | −156—−290% | −39—−272% | −33—−233% | −37—−300% | −46*—−364% | −45—−385% | −45—−438% | −47—−624% | −46r−51*—−596% | −48r−11—−787% | −55r−13—−533% | −68r103—−2948% | −80*—−87.0% | |
| Income tax | — | — | — | — | — | — | — | — | — | — | — | — | 0*—0.0% | |
| Income from discontinued operations | 20−94.2%36.5% | −0.5−105%−3.2% | 13−96.3%88.9% | −1.4—−11.3% | 8.7*—68.3% | 9.0−75.6%77.7% | 343+717%3341% | −9.2−105%−121% | −4.6*—−59.5% | 37—609% | 42—407% | 171—7405% | — | |
| Net income including minority interests | −136−188%−253% | −39—−276% | −21−107%−144% | −38—−311% | −38*—−295% | −36—−307% | 298—2904% | −57−155%−744% | −51*—−656% | −11—−178% | −13—−125% | 103—4457% | −80*—−87.0% | |
| Net income attributable to shareholders | −136−188%−253% | −39—−276% | −21−107%−144% | −38—−311% | −38*—−295% | −36—−307% | 298—2904% | −57−155%−744% | −51*—−656% | −11—−178% | −13—−125% | 103—4457% | −80*—−87.0% | |
| Earnings per share, basic | — | -0.25—— | -0.13−105%— | -0.28—— | — | -0.31—— | 2.57—— | -0.49−154%— | — | -0.09—— | -0.11—— | 0.91—— | — | |
| Earnings per share, diluted | — | -0.25—— | -0.13−105%— | -0.28−111%— | — | -0.31—— | 2.57—— | 2.57r-0.49+182%— | — | -0.09—— | -0.11—— | 0.91r0.83—— | — | |
| Shares, weighted average (basic) | 155+33.3%— | 155+33.3%— | 155+33.4%— | 136+17.7%— | — | 116+0.9%— | 116+1.1%— | 116+2.8%— | — | 115—— | 115—— | 113—— | — | |
| Shares, weighted average (diluted) | 155+33.3%— | 155+33.3%— | 155+33.4%— | 136+17.5%— | — | 116+0.9%— | 116+1.1%— | 116r116+3.0%— | — | 115—— | 115—— | 113r126—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 53—31.3% | 53−48.2%31.3% | 83−61.8%43.4% | 115+39.8%43.3% | 89−29.5%34.4% | 103+5.8%20.0% | 217+36.2%49.4% | 82−68.3%22.2% | 126+22.4%28.1% | 98—19.3% | 159—23.6% | 260—34.0% | 103—16.3% | |
| Short-term investments | 30—17.6% | 30−65.9%17.6% | 22+7.9%11.7% | 52—19.5% | 83—32.2% | 88—17.1% | 21—4.7% | — | — | — | — | — | 15—2.4% | |
| Receivables | 14—8.0% | 14+48.4%8.0% | 14+172%7.3% | 22−63.5%8.3% | 18−84.0%6.9% | 9.2−94.5%1.8% | 5.1−97.1%1.2% | 60−76.0%16.3% | 111−57.3%24.8% | 168—33.2% | 175—26.0% | 252—33.0% | 261—41.4% | |
| Inventory | 4.8—2.8% | 4.8+136%2.8% | 5.7+25.6%3.0% | 4.8+37.2%1.8% | 3.2−24.6%1.2% | 2.0−95.7%0.4% | 4.5−92.7%1.0% | 3.5−94.3%0.9% | 4.2r70−93.3%0.9% | 48—9.4% | 62—9.2% | 62—8.1% | 63—9.9% | |
| Other current assets | 5.8—3.4% | 5.8−33.0%3.4% | 5.4−54.3%2.8% | 9.4−41.1%3.5% | 6.2−39.0%2.4% | 8.7−38.6%1.7% | 12−15.0%2.7% | 16+13.1%4.3% | 10r12−7.9%2.3% | 14—2.8% | 14—2.0% | 14—1.8% | 11—1.8% | |
| Current assets | 114—66.7% | 114−75.2%66.7% | 134−64.8%70.0% | 206−33.6%77.5% | 207−39.5%80.0% | 461+24.9%89.2% | 380−31.9%86.5% | 310−50.6%83.6% | 342−28.2%76.2% | 369—73.1% | 558—82.7% | 627—82.2% | 476—75.5% | |
| Property, plant and equipment | 0.7—0.4% | 0.7−60.1%0.4% | 0.9−54.6%0.5% | 1.1−51.5%0.4% | 1.3−47.8%0.5% | 1.6−43.9%0.3% | 1.9−42.8%0.4% | 2.3−46.1%0.6% | 2.6r2.8−49.7%0.6% | 2.9—0.6% | 3.3—0.5% | 4.2—0.5% | 5.1—0.8% | |
| Right-of-use (leased) assets | — | — | — | — | 3.0−34.6%1.1% | — | — | — | 4.5−23.6%1.0% | — | — | — | 5.9—0.9% | |
| Goodwill | — | — | — | — | — | — | — | — | — | — | — | — | 0.9—0.1% | |
| Other intangible assets | 18—10.6% | 18−12.1%10.6% | 19−20.1%9.8% | 19−19.7%7.3% | 20−19.3%7.7% | 21−19.0%4.0% | 23−11.8%5.3% | 24−14.6%6.5% | 25−65.4%5.5% | 25—5.0% | 27—3.9% | 28—3.7% | 72—11.4% | |
| Total assets | 171—100% | 171−66.9%100% | 191−56.5%100% | 266−28.3%100% | 258−42.4%100% | 517+2.3%100% | 439−34.9%100% | 371−51.4%100% | 449−28.8%100% | 505—100% | 675—100% | 764—100% | 630—100% | |
| Accounts payable | 15—8.5% | 15−41.7%8.5% | 13−65.0%6.9% | 11−72.0%4.3% | 9.9−65.2%3.8% | 25+13.7%4.8% | 38−51.0%8.6% | 41+6.9%11.0% | 28−19.2%6.3% | 22—4.3% | 77—11.4% | 38—5.0% | 35—5.6% | |
| Current liabilities | 76—44.2% | 76−79.7%44.2% | 76−71.4%39.5% | 132−48.1%49.7% | 140−50.4%54.3% | 372+26.0%72.1% | 264−43.1%60.0% | 255−52.6%68.7% | 283−14.7%63.1% | 296—58.5% | 463—68.6% | 538—70.5% | 332—52.7% | |
| Lease liabilities (non-current) | — | — | 0.5—0.2% | — | 1.5−55.7%0.6% | — | — | — | 3.3−34.0%0.7% | — | — | — | 5.0—0.8% | |
| Total liabilities | 146—85.2% | 146−66.0%85.2% | 130−59.2%68.2% | 187−66.2%70.4% | 197−66.0%76.4% | 429−27.7%83.0% | 320−57.9%72.7% | 555−34.4%149% | 581−29.5%129% | 593—117% | 759—112% | 845—111% | 823—131% | |
| Retained earnings | −1,481—−866% | −1,481—−866% | −1,442—−754% | −1,421—−534% | −1,383—−535% | −1,345—−260% | −1,310—−298% | −1,608—−433% | −1,551—−346% | −1,500—−297% | −1,490—−221% | −1,477—−193% | −1,580—−251% | |
| Shareholders' equity | 25—14.8% | 25−71.2%14.8% | 61−49.2%31.8% | 79—29.6% | 61—23.6% | 88—17.0% | 120—27.3% | −183—−49.4% | −132—−29.4% | −88—−17.4% | −84—−12.5% | −82—−10.7% | −193—−30.7% | |
| Total liabilities and equity | 171—100% | 171−66.9%100% | 191−56.5%100% | 266−28.3%100% | 258−42.4%100% | 517+2.3%100% | 439−34.9%100% | 371−51.4%100% | 449−28.8%100% | 505—100% | 675—100% | 764—100% | 630—100% | |
| Shares outstanding | 155—— | 155+32.9%— | 154+32.9%— | 154+33.1%— | 121+4.8%— | 116+0.9%— | 116+0.9%— | 116+2.1%— | 116+3.0%— | 115—— | 115—— | 113—— | 112—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 2.9+163%5.4% | 0.9*+184%6.0% | 0.9*+187%6.0% | 0.9+120%7.2% | 0.3*+200%2.4% | 0.3−25.0%2.6% | 0.3−40.0%2.9% | 0.4−33.3%5.3% | 0.1r0.3*−85.7%1.3% | 0.4—6.6% | 0.5—4.9% | 0.6—26.0% | 0.7*—0.8% | |
| Share-based compensation | 11−44.4%21.3% | 3.7+8.6%25.8% | 2.6−52.4%18.1% | 2.4−55.6%19.4% | 2.8*−56.4%21.8% | 3.4−50.7%29.3% | 5.4−25.0%52.9% | 5.4−26.6%70.7% | 6.4*−40.9%82.6% | 6.9—113% | 7.2—70.2% | 7.3—317% | 11*—11.8% | |
| Cash from operating activities | −174—−324% | −34*—−238% | −62*—−434% | −58—−470% | −20*−169%−155% | −46*—−400% | −47*−178%−455% | −26—−340% | 29*—370% | −62*—−1025% | 60*—580% | −47—−2026% | −13*—−14.1% | |
| Capital expenditure | — | — | — | — | — | — | — | — | — | — | — | — | −0.0*—−0.0% | |
| Cash from investing activities | 50−86.8%92.9% | −7.6*—−53.3% | 30*−93.6%207% | 31—249% | −2.8*—−22.3% | −67*−15241%−581% | 463*+1573%4512% | −17−109%−230% | −0.5*−102%−7.0% | 0.4*—7.3% | 28*—269% | 203—8785% | 35*—38.5% | |
| Debt issued | — | — | — | — | — | — | — | — | — | −0.1*—−2.3% | — | — | — | |
| Debt repaid | — | — | — | — | — | — | — | — | 0*—0.0% | 0*—0.0% | — | — | — | |
| Shares issued | — | 0*—0.0% | 0*—0.0% | 54—436% | — | — | — | — | — | — | — | — | — | |
| Cash from financing activities | 74—138% | 12*+602200%84.4% | 0.1*—1.0% | 54—435% | 8.1*+3398%63.4% | 0.0*—0.0% | −282*—−2746% | −0.3−130%−3.5% | 0.2*−36.9%3.0% | −0.2*—−2.8% | −188*—−1825% | 0.9—38.4% | 0.4*—0.4% | |
| Change in cash | −50−987%−93.2% | −30*—−207% | −32*−124%−226% | 26—214% | −14*−151%−114% | −114*—−981% | 134*—1312% | −44−128%−573% | 28*+25.0%366% | −62*—−1020% | −101*—−976% | 157—6797% | 23*—24.7% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Coherus Oncology, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Toripalimab$41 M97%+113%
- Other revenue$1 M3.2%-82%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Executive pay at Coherus Oncology, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Mr. Dennis Lanfear | $2.7 M | $2.8 M | $1.2 M | $18 |
| 2024Chief executive | $4.8 M | $2.4 M | $1.3 M | $17 |
| 2023Chief executive | $5.9 M | $1.7 M | $1.9 M | $42 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Coherus Oncology, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Delisting notice 1 · Auditor changed 1 · Acquisition or sale completed 1 · Directors and officers 2 · Material agreement 2 · Agreement ended 1 · New debt 1 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 10
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Material agreementAgreement endedNew debt | 8-K | |
| Results announced | 8-K | |
| Auditor changed | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Shareholder vote | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Acquisition or sale completed | 8-K | |
| Material agreement | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 9, 2026
Acquisitions and funding#
4 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Dec 2017 | $7 M | Private placement after listing | $2 to $10 million | 1 | equity | SEC |
| Sep 2015 | $10 M | Private placement after listing | $10 to $50 million | 1 | equity | SEC |
| May 2014 | $56 M | No. 4 | $50 to $250 million | 35 | equity | SEC |
| Jul 2013 | $28 M | No. 3 | $10 to $50 million | 6 | debt, options | SEC |
| Jan 2012 | $46 M | No. 2 | $10 to $50 million | 23 | equity | SEC |
| Jul 2011 | $13 M | No. 1 | $10 to $50 million | 15 | debt, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
H-1B hiring at Coherus Oncology, Inc.#
1 labor condition applications certified in fiscal 2025 for 1 positions, at a median wage of $150 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Senior Scientist, Translational MedicineMolecular and Cellular Biologists | 1 | $150 K |
Where: Camarillo, CA 1
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2025 | 1 | 1 | $150 K | 1 |
| FY2024 | 1 | 1 | $115 K | 1 |
| FY2022 | 6 | 6 | $153 K | 6 |
| FY2020 | 4 | 4 | $105 K | 4 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Coherus BioSciences, Inc.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| 2017 | · | · | · | · | · | 51 | · | · | · | · | · | · | 51 |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing | |
| 51 people | Restructuring planSEC 8-K | “Under this plan, the Company reduced its workforce by 51 employees (approximately 30%).” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Coherus Oncology, Inc. compares in Biotechnology
- Revenue$42 M · higher than 57% of 647
- Net margin-253.4% · higher than 22% of 408
- Revenue growth59.8% · higher than 75% of 438
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Coherus Oncology, Inc.🇺🇸 | — | — | -253.4% | +59.8% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
Sources and freshness
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 16, 2026
Figures from SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Coherus Oncology, Inc.? Verify and update this profile — free
Show Coherus Oncology, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.